Shareholders in Lakefront Biotherapeutics NV (AMS:LKFT) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects. The stock price has risen 4.6% to €31.22 over the past week, suggesting investors are becoming more optimistic. Whether the upgrade is enough to drive the stock price higher is yet to be seen, however.
Following the latest upgrade, the current consensus, from the six analysts covering Lakefront Biotherapeutics, is for revenues of €95m in 2027, which would reflect a sizeable 90% reduction in Lakefront Biotherapeutics' sales over the past 12 months. Before the latest update, the analysts were foreseeing €85m of revenue in 2027. The consensus has definitely become more optimistic, showing a nice increase in revenue forecasts.
Check out our latest analysis for Lakefront Biotherapeutics
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 85% by the end of 2027. This indicates a significant reduction from annual growth of 15% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 14% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Lakefront Biotherapeutics is expected to lag the wider industry.
The highlight for us was that analysts increased their revenue forecasts for Lakefront Biotherapeutics next year. They also expect company revenue to perform worse than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Lakefront Biotherapeutics.
Thirsting for more data? We have analyst estimates for Lakefront Biotherapeutics going out to 2028, and you can see them free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.